Allergy Therapeutics PLC
LSE:AGY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eros International Media Ltd
NSE:EROSMEDIA
|
IN |
Allergy Therapeutics PLC
Operating Income
Allergy Therapeutics PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Operating Income
-£33.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£9.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$14B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
10%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$742m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Animalcare Group PLC
LSE:ANCR
|
Operating Income
£5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Operating Income
£33.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
11%
|
|
Allergy Therapeutics PLC
Glance View
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
See Also
What is Allergy Therapeutics PLC's Operating Income?
Operating Income
-33.5m
GBP
Based on the financial report for Dec 31, 2025, Allergy Therapeutics PLC's Operating Income amounts to -33.5m GBP.
What is Allergy Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-20%
Over the last year, the Operating Income growth was -18%. The average annual Operating Income growth rates for Allergy Therapeutics PLC have been -7% over the past three years , and -20% over the past ten years .
